AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 141 min read$GH

Kalia Kumud sold $632K of GH

Kalia Kumud (Chief Information Officer) sold 4,000 shares of Guardant Health, Inc. (GH) at $158.05 ($0.63M total) on 2026-09-11.

Original reporting
SEC EDGAR · Kalia Kumud
Published Sep 14, 2026, 10:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 14, 2026, 10:22 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$GH
Neutral
medium confidence
Mentioned
$GH
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GHNeutralLow
01

Why it matters

The sale reduces insider ownership but does not change company fundamentals.

02

Market read

A routine insider sale with modest dollar value; limited trading relevance.

03

What to watch

Potential tax planning or liquidity needs for the insider; not necessarily a negative signal.

Relevance 5/10Novelty 8/10Timing: filing date 2026-09-14 (same‑day disclosure)

Background

Form 4 filings disclose insider transactions; investors monitor them for signals.

Company-level read

Ticker impact

$GHNeutralMedium confidence
Context

Chief Information Officer sold 4,000 shares for $632,193, reducing his stake to 39,794 shares.

Expected impact

Potential short-term downward pressure on GH price.

Evidence & confidence

Sale size is modest ($0.6M) for a mid‑cap biotech; market may view it as routine but could trigger slight sell‑off.

Market effects

Sector

Minimal impact on biotech sector; insider sales are common.

Regional

None

Global

Low

Counterpoint

What could challenge this read

Sale could be unrelated to company outlook; may present a buying opportunity if fundamentals remain strong.

Key entities

  • Company
    Guardant Health, Inc.

    US‑listed biotech (ticker GH).

  • Insider
    Kalia Kumud

    Chief Information Officer of Guardant Health.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

GH insider trading history →

Related articles

SEP 15
$GHMed

Guardant Health stock hits 52-week high at 176.68 USD

Guardant Health Inc. (GH) hit a 52-week high of $176.68, up 216.17% in a year. Q2 revenue grew 44% to $335M, beating expectations. Analysts raised price targets, with Stifel at $180 and TD Cowen at $210, both maintaining Buy ratings. Positive outlook driven by healthcare advancements and strong product performance.

investing.com2 min
SEP 5
$GHHighAI 9/10

Guardant Health (GH) Wins FDA Approval For First Liquid Biopsy In Advanced Breast Cancer

Guardant Health (GH) received FDA approval for Guardant360 CDx, a liquid biopsy test to monitor ctDNA in advanced breast cancer. The test guides treatment decisions before disease progression, targeting about 37,000 eligible patients in the US. This approval may influence oncologist testing habits, payer coverage, and Guardant's competitive position in cancer diagnostics.

simplywall.st2 min
SEP 4
$GHHighAI 9/10

Guardant Health Announces Landmark FDA Approval of Guardant360® CDx as Companion Diagnostic for AstraZeneca’s ETCAMAH™ (camizestrant) in Advanced Breast Cancer

Guardant Health (GH) received FDA approval for Guardant360 CDx as a companion diagnostic for AstraZeneca's ETCAMAH in advanced breast cancer. The approval, based on the SERENA-6 trial, showed a 56% reduction in disease progression risk when using ctDNA-guided treatment. The test is recommended for use every three months during therapy.

finance.yahoo.com2 min
AUG 25
$GHHighAI 9/10

Final judgement favours TwinStrand in Guardant patent case

TwinStrand Biosciences and the University of Washington won a patent infringement case against Guardant Health, with the court awarding $245.2M in damages and royalties. The judgement upholds a jury verdict that Guardant willfully infringed two patents and must pay a 6% royalty on relevant sales until 2033. The court also affirmed the validity of the patents in question.

pharmaphorum.com2 min